Fennec Pharmaceuticals Initiates PEDMARK® Clinical Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy FENC?
Source: Newsfilter
- Clinical Study Launch: Fennec Pharmaceuticals announced that the Tampa General Hospital Cancer Institute is initiating a clinical study to evaluate the clinical utility of PEDMARK® in reducing ototoxicity in adolescent and adult cancer patients receiving cisplatin, which is expected to provide crucial data for future clinical research.
- Ototoxicity Risk Assessment: The study will analyze real-world clinical data and audiology monitoring to improve strategies for managing ototoxicity, which is anticipated to enhance patients' quality of life and reduce long-term hearing loss due to ototoxicity.
- FDA Approval Context: PEDMARK® is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment, indicated for pediatric patients aged one month and older, representing significant market potential, especially among the approximately 500,000 cancer patients diagnosed annually.
- Collaborative Research Significance: The collaboration between Tampa General Hospital and the USF Health Morsani College of Medicine underscores the commitment to otoprotective strategies, which is expected to drive broader recognition of PEDMARK® in clinical applications, further solidifying Fennec Pharmaceuticals' leadership in the field of ototoxicity prevention.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FENC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FENC
Wall Street analysts forecast FENC stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.910
Low
13.00
Averages
14.67
High
18.00
Current: 5.910
Low
13.00
Averages
14.67
High
18.00
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fennec Pharmaceuticals Q4 2025 Earnings Report
- Disappointing Earnings: Fennec Pharmaceuticals reported a Q4 GAAP EPS of -$0.17, missing expectations by $0.21, indicating challenges in profitability that may affect investor confidence.
- Lackluster Revenue Growth: Despite a 73.8% year-over-year revenue increase to $13.78 million, the figure fell short of expectations by $0.95 million, reflecting intensified market competition and potential shortcomings in sales strategies.
- Strong Cash Position: As of December 31, 2025, the company had $36.8 million in cash and cash equivalents, representing a $10.2 million increase from the previous year, demonstrating effective cash management that supports future operations and R&D.
- No Debt Burden: Fennec Pharmaceuticals reported zero outstanding debt as of December 31, 2025, providing financial flexibility that may help mitigate risks in future investments and expansions.
See More
FENNEC PHARMACEUTICALS INC Reports Q4 2025 Net Product Sales of $13.8 Million
- Sales Performance: The pharmaceutical company reported net product sales of $13.8 million for the fourth quarter of 2025.
- Financial Outlook: The sales figures indicate a positive trend in the company's financial performance within the pharmaceutical sector.
See More
Fennec Pharmaceuticals Announces Financial Results for Q4 and Full Year 2025 Along with Business Update
Financial Results: The report covers the financial results for the fourth quarter and the full year of 2025 for a pharmaceutical company.
Business Update: It provides a business update, likely detailing performance metrics, strategic initiatives, and future outlook.
See More
FENNEC PHARMACEUTICALS Reports FY Basic EPS of USD -0.35
Pharmaceutical Industry Overview: The pharmaceutical sector is experiencing significant changes, driven by advancements in technology and regulatory shifts.
Market Trends: There is a growing emphasis on personalized medicine and biologics, which are reshaping treatment approaches and market dynamics.
Regulatory Challenges: Companies face increasing scrutiny from regulatory bodies, impacting drug approval processes and market entry strategies.
Financial Performance: The financial outlook for pharmaceutical companies remains mixed, with some reporting strong earnings while others struggle with patent expirations and competition.
See More
FENNEC PHARMACEUTICALS REPORTS FY SALES OF $44.6 MILLION
- Sales Performance: The pharmaceutical company reported sales of $44.6 million for its products.
- Market Impact: This sales figure indicates a significant presence in the market, reflecting the company's growth and product demand.
See More
Fennec Pharmaceuticals to Release Q4 Earnings on March 24
- Earnings Release Announcement: Fennec Pharmaceuticals is set to release its Q4 earnings on March 24, with analysts expecting an EPS of $0.04 and revenue of $14.73 million, providing investors with the latest insights into the company's financial health.
- Analyst Expectations: Analysts predict that Fennec's revenue will reach $14.73 million, reflecting the company's stable performance in the market; if actual results meet expectations, it could bolster investor confidence and potentially drive stock price increases.
- Stock Performance: On Monday, Fennec's stock gained 1.8%, indicating a positive market reaction to the upcoming earnings report, suggesting that investors are increasingly confident about the company's future growth prospects.
- Market Reaction Analysis: As the earnings report approaches, investor attention is heightened, and if the company can exceed analyst expectations, it may further propel stock price increases, enhancing its competitive position in the biopharmaceutical industry.
See More
Fennec Pharmaceuticals Q4 2025 Earnings Report
- Disappointing Earnings: Fennec Pharmaceuticals reported a Q4 GAAP EPS of -$0.17, missing expectations by $0.21, indicating challenges in profitability that may affect investor confidence.
- Lackluster Revenue Growth: Despite a 73.8% year-over-year revenue increase to $13.78 million, the figure fell short of expectations by $0.95 million, reflecting intensified market competition and potential shortcomings in sales strategies.
- Strong Cash Position: As of December 31, 2025, the company had $36.8 million in cash and cash equivalents, representing a $10.2 million increase from the previous year, demonstrating effective cash management that supports future operations and R&D.
- No Debt Burden: Fennec Pharmaceuticals reported zero outstanding debt as of December 31, 2025, providing financial flexibility that may help mitigate risks in future investments and expansions.
See More
FENNEC PHARMACEUTICALS INC Reports Q4 2025 Net Product Sales of $13.8 Million
- Sales Performance: The pharmaceutical company reported net product sales of $13.8 million for the fourth quarter of 2025.
- Financial Outlook: The sales figures indicate a positive trend in the company's financial performance within the pharmaceutical sector.
See More
Fennec Pharmaceuticals Announces Financial Results for Q4 and Full Year 2025 Along with Business Update
Financial Results: The report covers the financial results for the fourth quarter and the full year of 2025 for a pharmaceutical company.
Business Update: It provides a business update, likely detailing performance metrics, strategic initiatives, and future outlook.
See More
FENNEC PHARMACEUTICALS Reports FY Basic EPS of USD -0.35
Pharmaceutical Industry Overview: The pharmaceutical sector is experiencing significant changes, driven by advancements in technology and regulatory shifts.
Market Trends: There is a growing emphasis on personalized medicine and biologics, which are reshaping treatment approaches and market dynamics.
Regulatory Challenges: Companies face increasing scrutiny from regulatory bodies, impacting drug approval processes and market entry strategies.
Financial Performance: The financial outlook for pharmaceutical companies remains mixed, with some reporting strong earnings while others struggle with patent expirations and competition.
See More
FENNEC PHARMACEUTICALS REPORTS FY SALES OF $44.6 MILLION
- Sales Performance: The pharmaceutical company reported sales of $44.6 million for its products.
- Market Impact: This sales figure indicates a significant presence in the market, reflecting the company's growth and product demand.
See More
Fennec Pharmaceuticals to Release Q4 Earnings on March 24
- Earnings Release Announcement: Fennec Pharmaceuticals is set to release its Q4 earnings on March 24, with analysts expecting an EPS of $0.04 and revenue of $14.73 million, providing investors with the latest insights into the company's financial health.
- Analyst Expectations: Analysts predict that Fennec's revenue will reach $14.73 million, reflecting the company's stable performance in the market; if actual results meet expectations, it could bolster investor confidence and potentially drive stock price increases.
- Stock Performance: On Monday, Fennec's stock gained 1.8%, indicating a positive market reaction to the upcoming earnings report, suggesting that investors are increasingly confident about the company's future growth prospects.
- Market Reaction Analysis: As the earnings report approaches, investor attention is heightened, and if the company can exceed analyst expectations, it may further propel stock price increases, enhancing its competitive position in the biopharmaceutical industry.
See More
